---
title: "CMPX - Glitch in the Matrix"
url: "https://www.readplaza.com/posts/cmpx-glitch-in-the-matrix-q6v"
author: "Null (@basednull)"
type: "claim"
status: "active"
claim_sentence: "Compass Therapeutics, Inc. (CMPX) will announce a regulatory filing for tovecimig from the COMPANION-002 trial in biliary tract cancer before December 31, 2026."
direction: "bullish"
ticker: "CMPX"
ticker_name: "Compass Therapeutics, Inc."
published: "2026-05-02T00:38:28.832+00:00"
updated: "2026-05-22T12:45:31.489318+00:00"
resolution_at: "2027-01-01T00:00:00+00:00"
access: "public"
tags: ["Value Investing", "Biotech / Pharma", "Medium term", "Small", "Biotech / Pharma", "Value Investing", "Small Cap", "Medium term", "Drug Development", "Fundamental Analysis", "Due Diligence", "Market Sentiment"]
---

# CMPX - Glitch in the Matrix

> Claim: Compass Therapeutics, Inc. (CMPX) will announce a regulatory filing for tovecimig from the COMPANION-002 trial in biliary tract cancer before December 31, 2026.

<p>This is a true value play. The trading bots got confused by the headline and tanked the price. This company is trading at its cash value.</p><p>Humans realize they screwed up. The analyst kept their predictions unchanged and the COA loaded up on the stock.</p><p>Here is an AI slop summary. Basically, the drug worked. They gave it to the control group.. it worked again. This threw off the data.</p><p>CMPX reported results from its&nbsp;<strong>COMPANION-002 Phase 2/3 trial</strong>&nbsp;for&nbsp;<strong>tovecimig</strong>&nbsp;in&nbsp;<strong>biliary tract cancer</strong>.</p><p><strong>The good news</strong></p><p>The drug&nbsp;<strong>worked on disease control metrics</strong>:</p><p>*&nbsp;<strong>Progression-Free Survival (PFS):</strong>&nbsp;Patients on tovecimig + paclitaxel stayed progression-free&nbsp;<strong>4.7 months vs 2.6 months</strong>&nbsp;for control.</p><p>*&nbsp;<strong>Response rate improved</strong>: Tumor response was&nbsp;<strong>17.1% vs 5.3%</strong>.</p><p>Those are statistically meaningful signals. &nbsp;</p><p><strong>The bad news (what the market cared about)</strong></p><p>The trial&nbsp;<strong>did not show a clean Overall Survival (OS) benefit</strong>, which is often the gold standard in oncology.</p><p>Why?</p><p>Because&nbsp;<strong>54% of the control patients crossed over</strong>&nbsp;into the treatment arm during the trial. That contaminated the survival comparison.</p>

## Author profile
Null (@basednull)

Stats: 4 posts, 0 followers, 1 following